Publications by authors named "J A O'Kelly"
Article Synopsis
- - Evidence on osteoporosis treatments like denosumab and oral bisphosphonates shows variation in effectiveness due to differing populations, clinical practices, and study methodologies, which can affect treatment outcome comparisons.
- - This study analyzed 280,288 women over 50, comparing denosumab and oral bisphosphonates by using propensity score techniques to ensure the treatment groups were comparable before estimating treatment effects.
- - Results indicated that achieving balance in observed covariates was generally successful after applying propensity score methods, but some residual confounding was still present, depending on the databases used and analysis methods applied.
Introduction: Clinicians frequently rely on patients to accurately tell them what prescription medications and doses they are taking in outpatient visits. This information is essential to monitor the efficacy of a medication and to determine any adverse interactions. This study aimed to assess urologist and urology trainee's visual recognition of common urology medications.
View Article and Find Full Text PDFIntroduction: There is a lack of data regarding the peri-operative and long-term outcomes of kidney transplantation in cystic fibrosis (CF) patients. Herein, we report the peri-operative and long-term outcomes of kidney transplantation in CF patients.
Materials And Methods: All CF patients who received a kidney transplant at the national kidney transplant center between 1993 and 2022 were identified.
Article Synopsis
- - The study evaluated real-world usage of the adalimumab biosimilar ABP 501 for treating inflammatory bowel disease (IBD) by analyzing pharmacy claims data from Germany and France.
- - It included 3362 German and 733 French patients, finding that 54.4% in Germany and 65.3% in France were new to ADA products; median treatment persistence varied between groups, with ADA-naïve patients showing slightly shorter persistence times.
- - Around 53.7% of German patients and 51.0% of French patients adhered to ABP 501 during the first year, while approximately 20% switched to other therapies, often to the original adalimumab reference product
Article Synopsis
- A study utilized data from the French national health insurance database to analyze the effectiveness of various osteoporosis medications (denosumab, zoledronic acid, oral bisphosphonates, raloxifene, and teriparatide) on reducing fracture risk in women over 55 years old.
- It followed five cohorts and compared fracture incidences over two years after starting treatment, highlighting a significant reduction in vertebral fractures for all medications.
- While denosumab showed efficacy in reducing hip fracture risk and nonvertebral fractures, oral bisphosphonates displayed an increased risk for hip fractures, indicating varied effectiveness among the treatments in real-world conditions.